<DOC>
	<DOCNO>NCT02899091</DOCNO>
	<brief_summary>The objective study evaluate safety potential therapeutic effect CB-AC-02 Intravenous Transplantation patient Alzheimer ' disease comprise 2 treatment cohort :</brief_summary>
	<brief_title>Evaluation Safety Potential Therapeutic Effects After Intravenous Transplantation CB-AC-02 Patients With Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>1 . Korean male female 50+ year age time screen visit 2 . Diagnosis Probable Alzheimer disease ( probable AD ) accord NINCDSADRDA criterion Screening visit 3 . Positive Amyloid amyloidligand PET 4 . A subject imaging finding Alzheimer 's disease confirm MRI PET Presence brain atrophy brain MRI visual assessment Presence reduce brain glucose metabolism bilateral temporalparietal lobe FDGPET 5 . Korea MiniMental State Examination ( KMMSE ) score 1026 time screen visit 6 . Presence caregiver provide information subject 's condition 7 . Subject take stable dose Alzheimer medication last 2 month 8 . Subject inform clinical trial sign consent form ( unable sign , consent legally acceptable representative require ) 1 . Concurrent Dementia result disorder [ i.e . infectious disease central nervous system HIV , syphilis , head injury , CreutzfeldJacob disease , Picks disease , Huntington 's disease , Parkinson 's disease , subdural hematoma , hydrocephalus structural brain lesion , drug addiction , alcoholism , substance abuse , thyroid disease , parathyroid disease , vitamins nutritional deficiency vascular etc . ] 2 . Subject vascular dementia determine clinical criterion DSMIV image criterion Erkinkuntii 3 . Subject severe white matter hyperintensities ( i.e . ≥ 25mm deep white matter ≥ 10mm periventricular capping/banding length ) 4 . Abnormal laboratory finding screen visit : A. ALT AST ≥ 2.5 time upper limit normal value B. Serum creatinine ≥ 1.5 time upper limit normal value C. Total bilirubin ≥ 2 time upper limit normal value D. Total WBC count &lt; 3,000/㎣ E. Hemoglobin &lt; 9.5g/dL men &lt; 9.0g/dL woman F. Platelet count &lt; 150,000/㎣ screen visit G. PT ( INR ) ≥ 1.5 aPTT ≥ 1.5 time upper limit normal value 5 . Subjects positive HIV , syphilis active HBV , HCV infection 6 . Subjects poor medical condition subject severe cardiovascular , gastrointestinal , pulmonary endocrinologic disease A . Suspected active active lung disease chest Xray screen visit B . Diagnosis cancer ( except subject remain complete remission 5 year ) 7 . Subject concurrent unstable psychiatric disorder ( i.e . severe depression , schizophrenia , bipolar disorder , etc ) 8 . Pregnant lactate woman 9 . Women childbearing age reject practice contraception one follow method Use condom Use contraceptive ( oral , dermal , injectable ) Use intrauterine contraceptive device 10 . Subjects history alcohol abuse ( &gt; 30g/day ) drug abuse 11 . Subjects undergo test perform clinical trial ( example , MRI , CT , PET , CSF study ) 12 . Subjects know allergy protein product ( Bovine serum ) , antibiotic ( gentamycin ) DMSO 13 . Subjects principal investigator considers inappropriate participation theis study</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>Mesenchymal Stem cell</keyword>
</DOC>